Skip to main content
Britannia Life Sciences logo

Britannia Life Sciences — Investor Relations & Filings

Ticker · BLAB ISIN · CA11042D1087 LEI · 549300PN0TMPKNE2R614 CSE Professional, scientific and technical activities
Open in API
Filings indexed 493 across all filing types
Latest filing 2026-05-21 Transaction in Own Shar…
Country CA Canada
Listing CSE BLAB

About Britannia Life Sciences

https://britannia.life/

Britannia Life Sciences operates as a global, vertically diversified product development platform, offering an integrated suite of services that function as a "one-stop-shop" across the entire product lifecycle, from concept to consumer. The company specializes in quality assurance, safety assessment, regulatory compliance, and comprehensive product testing. Core services are delivered through an ISO 17025 accredited laboratory, supporting businesses in the cosmetics, consumer packaged and household goods, nutraceutical, food, and general wellness sectors. The platform includes specialized divisions such as Britannia Labs, which serves the global cannabis industry, and Proof Wellness, an online marketplace for CBD consumers. The company focuses on leveraging its expertise to support clients primarily targeting the UK and European markets.

Recent filings

Filing Released Lang Actions
News release - English.pdf
Transaction in Own Shares Classification · 90% confidence The document is a corporate update press release (via Newsfile) detailing the company’s asset position and strategic direction, with the key announcement being the Board’s approval to commence a normal course issuer bid (NCIB) to repurchase its own shares. It does not contain full financial statements or call transcripts, nor is it an annual or interim report. This type of share repurchase program announcement falls under ‘Transaction in Own Shares’ (POS).
2026-05-21 English
News release - English.pdf
Transaction in Own Shares Classification · 85% confidence The document is a press release providing a corporate update that primarily announces the board’s approval and commencement of a Normal Course Issuer Bid (NCIB), detailing the proposed share repurchase program (maximum shares, duration, funding, etc.). This is not a financial report, governance guideline, or earnings announcement. It is a transaction in own shares (share buyback) announcement. Therefore, it fits the “Transaction in Own Shares” category (Code: POS).
2026-05-21 English
52-109FV2 - Certification of interim filings - CFO (E).pdf
Regulatory Filings
2026-03-02 English
Interim MD&A - English.pdf
Regulatory Filings
2026-03-02 English
Interim financial statements/report – English.pdf
Regulatory Filings
2026-03-02 English
Form of proxy - English.pdf
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a 'Form of Proxy' for Britannia Life Sciences Inc. for an upcoming Annual General Meeting. It provides instructions for shareholders to appoint a proxyholder and vote on specific agenda items like the election of directors and appointment of auditors. This document is a standard solicitation material sent to shareholders to request their votes, which falls under the definition of Proxy Solicitation & Information Statement.
2026-02-03 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.